SPPI "announced promising results from pre-clinical testing of experimental drug 
                             poziotinib in treating non-small-cell lung cancer (NSCLC). Encouraging pre-clinical results
                             sometimes boost small biotech stocks with no approved products, but Spectrum has six
                             products already on the market. No one would have been surprised if late-stage results
                             served as a nice catalyst for Spectrum. However, it's practically unheard of for a stock like
                             Spectrum to soar on pre-clinical data.  Keep in mind, though, that poziotinib is also in a
                             couple of phase 2 studies targeting NSCLC and breast cancer. The pre-clinical results
                             showed that in vitro responses for the drug in NSCLC could be much more effective
                             than AstraZeneca's Tagrisso and Boehringer Ingelheim's Gilotrif. If these results are
                             also demonstrated in Spectrum's phase 2 study for NSCLC, the company could have a
                             huge winner on its hands.
"  (Italics added here.)